| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
| Targets |
TD-139 targets galectin-3, a carbohydrate-binding protein involved in fibrosis, inflammation, and cancer. It binds galectin-3 with high affinity (Kd = 14 nM) and inhibits its function. Galectin-3 is secreted by macrophages and promotes fibroblast proliferation and collagen production. TD-139 disrupts the β-galactoside-binding activity of galectin-3 and promotes M2-like macrophage polarization.
|
|---|---|
| ln Vitro |
In vitro, TD-139 has a high affinity for galectin-3 with a Kd of 14 nM and 10 nM for galectin-1, but low affinity for galectins 2, 4N, 4C, 7, 8N, or 9N. It selectively targets galectin-3 by disrupting β-galactoside-binding activity.
|
| ln Vivo |
No independent in vivo efficacy data are widely reported for TD-139. As a research drug, it has been evaluated in clinical trials for idiopathic pulmonary fibrosis. In vivo characterization, including pharmacokinetics, efficacy, and toxicity, has been reported as part of clinical studies.
|
| Enzyme Assay |
For non-cell binding assays, recombinant galectin-3 is incubated with TD-139 and a fluorescent galectin-3 ligand. Binding affinity (Kd) is measured by fluorescence polarization or surface plasmon resonance.
|
| Cell Assay |
In cell assays, macrophages are treated with TD-139. Galectin-3 secretion is measured by ELISA. Macrophage polarization is assessed by flow cytometry for M1/M2 markers. Cell viability is measured by MTT.
|
| Animal Protocol |
In vivo animal protocols use mice with bleomycin-induced pulmonary fibrosis. TD-139 is administered by inhalation. Lung fibrosis is assessed by histology and collagen content. Pharmacokinetic parameters are determined by LC-MS.
|
| References | |
| Additional Infomation |
Olitigaltin has been investigated for the treatment of idiopathic pulmonary fibrosis. Olitigaltin is an inhaled, small-molecule galactolectin-3 (Gal-3) inhibitor with potential anti-fibrotic activity. After administration, Olitigaltin inhibits the activity of Gal-3. This may prevent the activation of alveolar macrophages and fibroblasts, thereby reducing pulmonary fibrosis. Gal-3 is a β-galactosidase-binding lectin expressed in multiple cell types, including macrophages, fibroblasts, activated T lymphocytes, and epithelial cells. Gal-3 expression is upregulated in fibrotic lung diseases, including idiopathic pulmonary fibrosis (IPF) and collagen vascular disease-associated interstitial pneumonia (CVD-IP), and it plays an important role in the fibrotic process of multiple organs. It is also frequently dysregulated in cancer and may play a role in angiogenesis, cell proliferation, and cell survival.
|
| Molecular Formula |
C28H30F2N6O8S
|
|---|---|
| Molecular Weight |
648.6350
|
| Exact Mass |
648.181
|
| CAS # |
1450824-22-2
|
| PubChem CID |
73774610
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
1017.2±75.0 °C at 760 mmHg
|
| Flash Point |
569.0±37.1 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.761
|
| LogP |
2.19
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
45
|
| Complexity |
903
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
S([C@@]1([H])[C@@]([H])([C@]([H])([C@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])N1C([H])=C(C2C([H])=C([H])C([H])=C(C=2[H])F)N=N1)O[H])[C@@]1([H])[C@@]([H])([C@]([H])([C@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])N1C([H])=C(C2C([H])=C([H])C([H])=C(C=2[H])F)N=N1)O[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~77.1 mM; with ultrasonication)
H2O: < 0.1 mg/mL (insoluble) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (3.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. View More
Solubility in Formulation 4: 3.33 mg/mL (5.13 mM) in 10% HP-β-CD in Saline water (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication. Solubility in Formulation 5: 10 mg/mL (15.42 mM) in 45% PEG300 + 5% Tween-80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 6: 2 mg/mL (3.08 mM) in 15% Cremophor EL + 85% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5417 mL | 7.7084 mL | 15.4169 mL | |
| 5 mM | 0.3083 mL | 1.5417 mL | 3.0834 mL | |
| 10 mM | 0.1542 mL | 0.7708 mL | 1.5417 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.